{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:04:59Z","timestamp":1776449099047,"version":"3.51.2"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2021-KH119723"],"award-info":[{"award-number":["RS-2021-KH119723"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["grant from the Medical Data-Driven Hospital Support Project through the Korea Health Information Service"],"award-info":[{"award-number":["grant from the Medical Data-Driven Hospital Support Project through the Korea Health Information Service"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015098","name":"Seoul Metropolitan Government Seoul National University Boramae Medical Center","doi-asserted-by":"publisher","award":["04-2024-0032"],"award-info":[{"award-number":["04-2024-0032"]}],"id":[{"id":"10.13039\/501100015098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Background<\/jats:title>\n A treat-to-target strategy involving treatment modification improves outcomes in gout, but evidence remains limited regarding the optimal approach when initial urate-lowering therapy (ULT) fails. This study aimed to investigate real-world ULT sequence patterns and evaluate treatment retention based on the initial agent, modification type, and comorbidities.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n We analyzed electronic health record data collected from 2010 to 2022 from the common data model databases of two hospitals. Adults aged 18 years or older diagnosed with gout who initiated ULT and were followed for at least 2 years were included. Outcomes included the frequency and sequence of ULT prescriptions. Treatment modification, defined as switching to another ULT or adding an additional agent, was considered the end of retention for the previous regimen. Subgroup analyses were performed based on comorbidity.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 2220 patients, febuxostat was the most common first-line agent (51.4%), with 90.9% maintaining therapy. Among those who modified febuxostat therapy, switchers and add-on users continued treatment similarly (91.5%\n vs<\/jats:italic>\n . 86.8%,\n P<\/jats:italic>\n \u2009=\u20090.33). Of allopurinol initiators, 55.8% changed therapy, mainly switching to febuxostat or benzbromarone rather than adding another agent (51.4%\n vs<\/jats:italic>\n . 4.1%,\n P<\/jats:italic>\n \u2009<\u20090.001), with similar retention rates (91.5%\n vs<\/jats:italic>\n . 86.8%,\n P<\/jats:italic>\n \u2009=\u20090.33). Among benzbromarone initiators, 57.2% changed therapy (switchers, 56.7%; add-on users, 0.5%;\n P<\/jats:italic>\n \u2009<\u20090.001), and retention rates were 90.5% and 100%, respectively (\n P<\/jats:italic>\n \u2009=\u20091.00). Chronic kidney disease was associated with low variability in ULT sequence.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n ULT demonstrated durable retention when used as first- or second-line treatment, with switching being more common than add-on therapy and maintaining similar retention rates.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0347654","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:33:37Z","timestamp":1776447217000},"page":"e0347654","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment sequence patterns of urate-lowering therapy in Korean patients with gout: A common data model-based study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-1415","authenticated-orcid":true,"given":"Min Jung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Gee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Yoon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borim","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-7598","authenticated-orcid":true,"given":"Kichul","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"pone.0347654.ref001","article-title":"Treating to target: A strategy to cure gout","author":"F Perez-Ruiz","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"pone.0347654.ref002","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"P Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"pone.0347654.ref003","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"JD FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"pone.0347654.ref004","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"M Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"10156","key":"pone.0347654.ref005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: A randomised controlled trial","volume":"392","author":"M Doherty","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"pone.0347654.ref006","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","article-title":"Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors","volume":"16","author":"M Dehlin","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"pone.0347654.ref007","first-page":"556","article-title":"What is allopurinol failure and what should we do about it?","volume":"51","author":"LK Stamp","year":"2024","journal-title":"J Rheumatol"},{"issue":"5","key":"pone.0347654.ref008","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3904\/kjim.2023.206","article-title":"Korean guidelines for the management of gout","volume":"38","author":"JJ Lee","year":"2023","journal-title":"Korean J Intern Med"},{"issue":"1","key":"pone.0347654.ref009","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf322","article-title":"Ten-year cardiovascular risk changes and major adverse events in gout patients","volume":"65","author":"B Ghang","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"pone.0347654.ref010","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6947-8-S1-S2","article-title":"Forty years of SNOMED: A literature review","volume":"8","author":"R Cornet","year":"2008","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"pone.0347654.ref011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-0038-1667077","article-title":"Recent Developments in clinical terminologies - SNOMED CT, LOINC, and RxNorm","volume":"27","author":"O Bodenreider","year":"2018","journal-title":"Yearb Med Inform"},{"issue":"4","key":"pone.0347654.ref012","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","article-title":"Normalized names for clinical drugs: RxNorm at 6 years","volume":"18","author":"SJ Nelson","year":"2011","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"pone.0347654.ref013","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1373\/49.4.624","article-title":"LOINC, a universal standard for identifying laboratory observations: A 5-year update","volume":"49","author":"CJ McDonald","year":"2003","journal-title":"Clin Chem"},{"key":"pone.0347654.ref014","doi-asserted-by":"crossref","first-page":"107081","DOI":"10.1016\/j.cmpb.2022.107081","article-title":"TreatmentPatterns: An R package to facilitate the standardized development and analysis of treatment patterns across disease domains","volume":"225","author":"AF Markus","year":"2022","journal-title":"Comput Methods Programs Biomed"},{"issue":"27","key":"pone.0347654.ref015","doi-asserted-by":"crossref","first-page":"7329","DOI":"10.1073\/pnas.1510502113","article-title":"Characterizing treatment pathways at scale using the OHDSI network","volume":"113","author":"G Hripcsak","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"pone.0347654.ref016","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.semarthrit.2021.04.011","article-title":"Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis","volume":"51","author":"C-N Son","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"pone.0347654.ref017","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.41550","article-title":"Trends in utilization of urate-lowering therapies following the US Food and Drug Administration\u2019s Boxed Warning on Febuxostat","volume":"73","author":"SC Kim","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"pone.0347654.ref018","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14397595.2020.1784556","article-title":"Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data","volume":"31","author":"R Koto","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"3","key":"pone.0347654.ref019","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"JR O\u2019Dell","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"pone.0347654.ref020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3904\/kjim.2016.429","article-title":"Prescription pattern of urate-lowering therapy in Korean gout patients: Data from the national health claims database","volume":"33","author":"J-W Kim","year":"2018","journal-title":"Korean J Intern Med"},{"issue":"3","key":"pone.0347654.ref021","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/1756-185X.14558","article-title":"Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis","volume":"26","author":"P-H Tsai","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"pone.0347654.ref022","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/acr.22067","article-title":"Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout","volume":"65","author":"SC Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"pone.0347654.ref023","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1007\/s10067-019-04739-3","article-title":"Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: A cost-effectiveness analysis for Spanish patients","volume":"38","author":"M Presa","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"5","key":"pone.0347654.ref024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40273-018-0643-4","article-title":"Cost-effectiveness analysis of lesinurad\/allopurinol versus febuxostat for the management of gout\/hyperuricemia in Italy","volume":"36","author":"M Ruggeri","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"pone.0347654.ref025","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.semarthrit.2018.06.004","article-title":"Combination urate-lowering therapy in the treatment of gout: What is the evidence?","volume":"48","author":"F Perez-Ruiz","year":"2019","journal-title":"Semin Arthritis Rheum"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:33:41Z","timestamp":1776447221000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347654"}},"subtitle":[],"editor":[{"given":"Sian Yik","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0347654","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]}}}